Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Recurrent ovarian cancer

Current developments give hope for a personalized approach

    • Congress Reports
    • Gynecology
    • Oncology
    • RX
  • 3 minute read

At the ESMO Congress in Amsterdam, a review was given of the options available to date in the treatment of recurrent ovarian cancer. Therapy depends on the particular form of recurrence and therefore aims either mainly at symptom improvement or at prolonging progression-free survival. In the future, new biomarkers or imaging agents can be used to personalize the drug approach  and thus significantly improve it in individual cases.

(ag) Prof. Ignace Vergote, MD, Leuven, presented current challenges in the field of recurrent ovarian cancer. First, the definition of this condition must be specified:

  • If the treatment-free interval since the last platinum dose >is 12 months, it is referred to as a platinum-sensitive form.
  • If this period is 6-12 months, one speaks of a partially platinum-sensitive form.
  • If the period is <6 months, it is called a platinum-resistant form.
  • If the period is <4 weeks, it is called a platinum-refractory form.

“The goals of treatment in recurrent ovarian cancer differ depending on platinum sensitivity: in resistant types (0-6 months), the main goal is symptom relief; in partially sensitive, the main goal is to stabilize the disease and delay progression or prolong progression-free survival. These goals are even more important in platinum-sensitive types,” said Prof. Vergote.

Platinum sensitive ovarian cancer

The following should be noted regarding platinum-sensitive ovarian cancer, according to Prof. Vergote:

  • Secondary cytoreductive surgery may be indicated in selected patients (DESKTOP and GOG trials).
  • The European Medicines Agency (EMA) has approved bevacizumab for the platinum-sensitive form.
  • Other anti-angiogenic drugs, PARP inhibitors, etc. are being studied in phase II/III trials.
  • Biological predictors that predict response are urgently needed to be identified.

Platinum-resistant ovarian cancer

In the platinum-resistant form, it is important to balance well the efficacy, toxicity, and timing of the active ingredients. Currently, however, the research field is experiencing a boom due to various studies on new active substances, which has already produced some interesting approaches and results. In addition to inhibiting angiogenesis, future drugs will be needed for other molecular targets that must first be confirmed genetically or by imaging.

Personalized approach

Prof. Bradley J. Monk, MD, Arizona, spoke about biomarkers: “This word has often been inaccurately applied. A biomarker is significant if it aligns with an important clinical indication, is reproducible, and provides a tangible benefit to the individual patient or improves management. This also always means very accurate validation of the biomarker and thus a good understanding of the underlying mechanisms.”
There are prognostic and predictive biomarkers. The former refer to individuals who are already ill. They are useful in predicting the outcome of treatment by comparing marker-positive with marker-negative patients without varying the drug intervention. Predictive biomarkers can be used to predict the outcome of specific targeted treatment in different populations. This can be useful in selecting a therapy for patients on an individual basis. For example, in platinum-sensitive recurrent serous ovarian cancer, one such treatment is PARP inhibitors. The treatment success seems to be partially dependent on the BRCA mutation.
Concomitant imaging agents may also predict response, e.g., etarfolatide. It binds to the folate receptor, which is overexpressed in several cancers, including ovarian cancer, indicating the location of the tumor and the potential response to treatment (e.g., using vintafolide, which is currently in development).

Current developments

Several promising drugs are in the pipeline:
Vintafolide: Vintafolide has orphan drug status and is currently under review in the EU based on data from the PRECEDENT study. Filing for approval in the U.S. is expected in 2015, based on the currently ongoing Phase III PROCEED trial.
MK-1775: MK-1775 is the only WEE1 kinase inhibitor currently in clinical development. It is an oral therapy that could be used in p53-deficient tumors. MK-1775 interferes with the G2 DNA “damage checkpoint” (by inhibiting WEE1), making tumor cells more vulnerable to chemotherapeutic agents that induce DNA damage. In combination with a DNA-destroying chemotherapy agent, this appears to allow promising response rates to be achieved in the platinum-refractory setting.

Source: “Is Personal Medicine a Reality for Recurrent Ovarian Cancer Patients?”, MSD satellite symposium at ESMO Congress, September 27-October 1, 2013, Amsterdam.

InFo Oncology & Hematology 2014; 2(1): 37-38.

Autoren
  • Andreas Grossmann
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • Amsterdam
  • Angiogenesis
  • biological predictors
  • Biomarker
  • BRCA mutation
  • ESMO
  • Folate receptor
  • imaging
  • platinum sensitive
  • PRECENDENT study
  • predictive
  • prognostic
  • Recurrence
  • recurrent ovarian cancer
  • Symptom
  • Vintafolid
Previous Article
  • 3rd Basel Dementia Forum

Dementia places high demands on physicians and the personal environment

  • Congress Reports
  • Geriatrics
  • Psychiatry and psychotherapy
  • RX
View Post
Next Article
  • Aliskiren

Good blood pressure control in combination with HCT

  • Angiology
  • Cardiology
  • Congress Reports
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Treatment of vitiligo

Focus on patient perspective and disease activity

    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 5 min
  • Vaccine-preventable respiratory diseases

RSV and pneumococci: recommendations for risk groups

    • Congress Reports
    • General Internal Medicine
    • Infectiology
    • Pediatrics
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 5 min
  • Circadian rhythm in asthma

Chronotherapy can improve control

    • Allergology and clinical immunology
    • General Internal Medicine
    • Pneumology
    • RX
    • Studies
View Post
  • 6 min
  • Update on diagnostics, risk stratification and therapy

Acute myeloid leukemia 2025

    • Education
    • Hematology
    • Oncology
    • RX
    • Studies
View Post
  • 4 min
  • New practice guideline for fibromyalgia syndrome

Good times, bad times

    • Congress Reports
    • General Internal Medicine
    • Neurology
    • Pharmacology and toxicology
    • Physical medicine and rehabilitation
    • Rheumatology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 5 min
  • Findings from the TRACK-FA study

Neuroimaging biomarkers in Friedreich’s ataxia

    • Genetics
    • Neurology
    • Pediatrics
    • RX
    • Studies
View Post
  • 12 min
  • Doing sport without fear or risk

Doing sport without fear or risk

    • CME continuing education
    • Endocrinology and Diabetology
    • Pediatrics
    • RX
    • Sports Medicine
View Post
  • 8 min
  • Chronic inducible urticaria

What has stayed the same, what has changed?

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    Doing sport without fear or risk
  • 2
    UV protection and skin cancer screening – Update 2025
  • 3
    Rare malignancy from a dermatological perspective
  • 4
    Yellow nail and Swyer-James syndrome
  • 5
    Diagnostic indications

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.